1. Home
  2. VTEX vs ANNX Comparison

VTEX vs ANNX Comparison

Compare VTEX & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VTEX

VTEX

VTEX

HOLD

Current Price

$3.60

Market Cap

755.3M

Sector

Technology

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$4.19

Market Cap

873.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTEX
ANNX
Founded
1999
2011
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
755.3M
873.3M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
VTEX
ANNX
Price
$3.60
$4.19
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$5.97
★ $16.50
AVG Volume (30 Days)
651.9K
★ 2.8M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.78
N/A
Revenue Next Year
$9.63
$16,320.74
P/E Ratio
$43.33
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.84
$2.54
52 Week High
$4.62
$7.18

Technical Indicators

Market Signals
Indicator
VTEX
ANNX
Relative Strength Index (RSI) 41.69 45.25
Support Level $3.45 $3.79
Resistance Level $3.74 $4.36
Average True Range (ATR) 0.07 0.24
MACD 0.01 0.02
Stochastic Oscillator 28.57 77.61

Price Performance

Historical Comparison
VTEX
ANNX

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: